Safety and efficacy of dapagliflozin in patients with type 2 diabetes mellitus during fasting in the month of Ramadan: an experience from tertiary care hospital-Reference-Cited by-同舟云学术

Safety and efficacy of dapagliflozin in patients with type 2 diabetes mellitus during fasting in the month of Ramadan: an experience from tertiary care hospital

Published:2024-07-29 Issue: Volume: Page:
ISSN:0973-3930
Container-title:International Journal of Diabetes in Developing Countries
language:en
Short-container-title:Int J Diabetes Dev Ctries

Author:

Baloch Akhtar Ali^ORCID,Shabir Khalil Ullah,Kiran Zareen,Fatima Nazish,Hasan Syed Muhammad

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13410-024-01380-y.pdf

Reference29 articles.

1. Abdelgadir E, Rashid F, Bashier A, Al Saeed M, Khalifa A, Alawadi F, et al. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes. Diabetes Metab Syndr: Clin Res Rev. 2019;13(5):2927–32.

2. Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, et al. Diabetes and Ramadan: practical guidelines. Diabetes Res Clin Prac. 2017;126:303–16.

3. Salti I, Bénard E, Detournay B, Bianchi-Biscay M, Le Brigand C, Cl Voinet, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27(10):2306–1.

4. Bravis V, Hui E, Salih S, Mehar S, Hassanein M, Devendra D. Ramadan education and awareness in diabetes (READ) programme for Muslims with type 2 diabetes who fast during Ramadan. Diabetic Med: J Br Diabet Assoc. 2010;27(3):327–31.

5. Bashir MI, Pathan MF, Raza SA, Ahmad J, Khan AKA, Ishtiaq O, et al. Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan. Indian J Endocrinol Metab. 2012;16(4):503–7.